Entry Point Capital, LLC Kiniksa Pharmaceuticals, Ltd. Transaction History
Entry Point Capital, LLC
- $246 Million
- Q3 2025
Shares
1 transactions
Others Institutions Holding KNSA
# of Institutions
7Shares Held
1.85MCall Options Held
0Put Options Held
0-
Pictet Asset Management Sa Geneva 73, V81.52MShares$61.2 Million0.03% of portfolio
-
Spearhead Capital Advisors, LLC Wellington, FL203KShares$8.17 Million2.82% of portfolio
-
Putnam Investments LLC Boston, MA39.5KShares$1.59 Million0.0% of portfolio
-
Birchview Capital, LP Burlington, VT30KShares$1.21 Million0.94% of portfolio
-
Credit Suisse Ag Zurich, V828.9KShares$1.17 Million0.0% of portfolio
About Kiniksa Pharmaceuticals, Ltd.
- Ticker KNSA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,470,400
- Market Cap $1.39B
- Description
- Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatm...